StreetInsider.com News Articles

Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: HERMAN JOAN E

Fri, 17 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26785129.html

Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: HERMAN JOAN E

Fri, 17 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26785129.html

Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: HANTSON LUDWIG

Fri, 17 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26785133.html

Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: HANTSON LUDWIG

Fri, 17 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26785133.html

Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: Reikes Peter N

Fri, 17 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26785136.html

Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: Reikes Peter N

Fri, 17 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260717/26785136.html

Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: BERTHELSEN SPENCER R

Fri, 17 Jul 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260717/26785125.html

Form 4 IONIS PHARMACEUTICALS For: Jul 15 Filed by: BERTHELSEN SPENCER R

Fri, 17 Jul 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260717/26785125.html

Wolfe Research Downgrades Ionis Pharmaceuticals (IONS) to Peerperform

Thu, 16 Jul 2026 02:22:53 -0400

Wolfe Research analyst Andy Chen downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Peerperform.

The analyst comments: “Downgrade IONS to Peer Perform. Fair value range $49-$79/share but stock unlikely to close in to this the upper end of the range. On the PT range, the upper end is supported by our DCF valuation. The bottom end accounts for the worst case scenario where Arrowhead succeeds and Lp(a) fails, while the rest of the stock remains stagnant.

Longer-term IONS may perform well on sHTG and potentially Angelman. We model $4.5B Tryngolza peak sales (vs buyside $2.5B), which is enough to support more than

Wolfe Research Downgrades Ionis Pharmaceuticals (IONS) to Peerperform

Thu, 16 Jul 2026 02:22:53 -0400

Wolfe Research analyst Andy Chen downgraded Ionis Pharmaceuticals (NASDAQ: IONS) from Outperform to Peerperform.

Longer-term IONS may perform well on sHTG and potentially Angelman. We model $4.5B Tryngolza peak sales (vs buyside $2.5B), which is enough to support more than

Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: BENNETT C FRANK

Wed, 15 Jul 2026 11:53:00 -0400

si-local-file:///var/storage/secattach/20260715/26772894.html

Form 4 IONIS PHARMACEUTICALS For: Jul 07 Filed by: BENNETT C FRANK

Wed, 15 Jul 2026 11:53:00 -0400

si-local-file:///var/storage/secattach/20260715/26772894.html

Ionis to hold second quarter 2026 financial results webcast

Wed, 15 Jul 2026 07:05:00 -0400

Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results and highlight progress on key programs.

The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has

Ionis to hold second quarter 2026 financial results webcast

Wed, 15 Jul 2026 07:05:00 -0400

Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time

The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has

Ionis to hold second quarter 2026 financial results webcast

Wed, 15 Jul 2026 07:05:00 -0400

Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time

The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has

Ionis to hold second quarter 2026 financial results webcast

Wed, 15 Jul 2026 07:05:00 -0400

Webcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern Time

The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has

Increasing unusual option volume: BCE EQPT MDY DOMO CC IONS ARKG FRMM TOI DINO

Wed, 15 Jul 2026 04:24:59 -0400

Increasing unusual option volume: BCE EQPT MDY DOMO CC IONS ARKG FRMM TOI DINO

Biogen presents Phase 2 data on Alzheimer's drug diranersen at AAIC

Tue, 14 Jul 2026 09:16:19 -0400

Biogen presented Phase 2 CELIA study data on diranersen, an investigational antisense oligonucleotide therapy targeting tau protein, at the Alzheimer's Association International Conference (AAIC) 2026. The drug was discovered by Ionis Pharmaceuticals (Nasdaq: IONS), which licensed it to Biogen in December 2019.

The CELIA study enrolled 416 participants with early Alzheimer's disease across three dose regimens administered intrathecally over 18 months. The 60 mg dose given every six months showed the strongest clinical response compared with placebo, with a 26% slowing of decline on the CDR-SB scale, 42% on ADAS-Cog13, and 50% on MMSE. The majority of these differences achieved nominal

Biogen presents Phase 2 data on Alzheimer's drug diranersen at AAIC

Tue, 14 Jul 2026 09:16:19 -0400

Biogen presents Phase 2 data on Alzheimer's drug diranersen at AAIC

Tue, 14 Jul 2026 09:16:19 -0400

Biogen presents Phase 2 data on Alzheimer's drug diranersen at AAIC

Tue, 14 Jul 2026 09:16:19 -0400

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Tue, 14 Jul 2026 09:16:00 -0400

- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SB -

- Biomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain tau pathology, as measured by PET, across all studied doses in a Phase 2 study -

- Dose response: CDR-SB results favored diranersen versus

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Tue, 14 Jul 2026 09:16:00 -0400

- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SB -
- Biomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain tau pathology, as measured by PET, across all studied doses in a Phase 2 study -
- Dose response: CDR-SB results favored diranersen versus

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Tue, 14 Jul 2026 09:16:00 -0400

- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SB -
- Biomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain tau pathology, as measured by PET, across all studied doses in a Phase 2 study -
- Dose response: CDR-SB results favored diranersen versus

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

Tue, 14 Jul 2026 09:16:00 -0400

- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical decline on the cognitive endpoints—42% on ADAS-Cog13 and 50% on MMSE—alongside a 26% slowing on CDR-SB -
- Biomarker response: Diranersen is the first tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain tau pathology, as measured by PET, across all studied doses in a Phase 2 study -
- Dose response: CDR-SB results favored diranersen versus